Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future.
Scope of this research
- Ovarian cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential
- Current treatment options for ovarian cancer and ongoing controversies
- Examination of the late-phase ovarian cancer pipeline, including drug profiles of late-stage agents
- Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Research and analysis highlights
Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent.
While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates.
R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce.
Key reasons to purchase this research
- Estimate the number of treatable patients and identify unmet needs for future drug development opportunities
- Understand the current treatment of the disease, as well as opportunities and threats in the ovarian cancer market
- Analyze the current ovarian cancer pipeline and the potential of late-stage drugs